Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 obeticholic acid trial in primary biliary cholangitis
NL-OMON46899Phase 3Active, not recruiting
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jul 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obeticholic acid in primary biliary cholangitis (PBC) (3 arms), sponsored by Intercept Pharmaceuticals. Primary endpoints: Composite biochemical responder endpoint and Safety. Started Jul 2012; status: active, not recruiting.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON46899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46899.